IFITM2 and neoplasm: IFITM2 was reported to sustain tumor progression and lymphatic metastasis by inducing cytokines release, while migration and invasion were inhibited by the IFITM2 downregulation in renal clear cell renal carcinoma (ccRCC) [27].